Ocugen (NasdaqCM:OCGN) just gave investors something to talk about by announcing a new licensing agreement that hands Kwangdong Pharmaceutical the exclusive rights to commercialize its gene therapy ...

New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Researchers at Tel Aviv University have developed a new approach for using locked nucleic acids (LNAs)—a particularly stable ...

Academic, industry, and FDA collaboration is key to personalized treatment manufacturing, says Aldevron’s Max Sellman at BPI this week.

Researchers in Berlin have used base editing to repair mutations that cause the kidney disorder ADPKD in cells from both mice ...

A genome-editing technique known as prime editing holds potential for treating many diseases by transforming faulty genes into functional ones. However, the process carries a small chance of inserting ...

At the European Cell & Gene Therapy Summit 2025, funding challenges and innovation drove discussions on the sector’s future.

The White House is clamping down on pharma’s ability to buy new molecules from Chinese biotechs; Sanofi, Merck and others ...

Jesse Gelsinger died after receiving a gene therapy treatment to treat a liver disease. The death sparked an investigation ...

First commercially available cell culture solution for HEK293 cells and perfusion - optimized for high cell density (HCD), ...